Promising HIV vaccine candidate passes early safety check in 57 volunteers

NCT ID NCT06033209

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new HIV vaccine candidate in 57 healthy adults without HIV. The goal was to see if the vaccine is safe and whether it triggers a specific immune response that could help fight the virus. Researchers used a special adjuvant to boost the vaccine's effect and compared different doses and schedules.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlanta - Hope Clinic

    Decatur, Georgia, 30030, United States

  • Bridge HIV CRS

    San Francisco, California, 94102, United States

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Columbia University Medical Center

    New York, New York, 100032, United States

  • New York Blood Center

    New York, New York, 10065, United States

  • Penn Prevention CRS [Site ID: 30310]

    Philadelphia, Pennsylvania, 19104, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • Vanderbilt Institute for Infection, Immunology and Inflammation

    Nashville, Tennessee, 37232-2582, United States